First Tracks Biotherapeutics Inc

NASDAQ:TRAX

Biotechnology

Healthcare
$44.50 -4.87%

-$0.89 today

Market cap
$1.87B
Beta
0.00
P/E (TTM)
-6.1
EPS (TTM)
-$2.81
52W Low $14.72High $26.80

Volume 0.75M

Average 0.43M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$142.93M

FY 2025 · Annual

Investing Cash Flow

$228.03M

FY 2025 · Annual

+139.0% YoY

Financing Cash Flow

$30.01M

FY 2025 · Annual

-74.5% YoY

Cash Flow Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(106.15M)(163.71M)(166.09M)
Depreciation & Amortization2.38M2.4M2.42M
Deferred Income Tax000
Stock-Based Compensation18.39M26.83M32.3M
Change in Working Capital2.9M18.99M(1.52M)
Accounts Receivables000
Inventory000
Accounts Payables8.39M17.81M0
Other Working Capital(5.49M)1.18M(1.52M)
Other Non-Cash Items(10.52M)(10.31M)(10.04M)
Operating Cash Flow(93M)(125.81M)(142.93M)
Capital Expenditures(807K)(358K)(87K)
Acquisitions (Net)000
Purchases of Investments(303.92M)(380.38M)0
Sales of Investments449.48M476.13M0
Other Investing Activities00228.12M
Investing Cash Flow144.75M95.4M228.03M
Debt Repayment000
Common Stock Issued0117.52M0
Common Stock Repurchased000
Dividends Paid000
Other Financing Activities0030.01M
Financing Cash Flow(87.09M)117.52M30.01M
Effect of Forex Changes000
Net Change in Cash(35.34M)87.12M115.12M
Free Cash Flow(93.81M)(126.16M)(143.01M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$166.1M
+ D&A$2.4M
+ Stock-Based Comp$32.3M
+ Deferred Tax$0
- Working Capital-$1.5M
- Other Non-Cash-$10.0M
= Operating Cash Flow-$142.9M
- Capex-$87.0K
= Free Cash Flow-$143.0M

Analysis

FY2025 free cash flow is -$143.0M. FCF conversion is 86.1% of net income. Operating cash flow was -$142.9M, with capex of -$87.0K. The largest bridge item is Stock-Based Comp at $32.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 12, 2026
SC 13G/ASC 13G/A filingNov 6, 2026
424B3424B3 filingNov 4, 2026
424B3424B3 filingNov 4, 2026
4Statement of changes in beneficial ownershipNov 3, 2026

Does TRAX generate free cash flow?

First Tracks Biotherapeutics Inc (TRAX) generated -$143.01M of free cash flow in fiscal 2025.

How much operating cash flow does TRAX produce?

Operating cash flow was -$142.93M, before capital expenditures of $87,000.00.